文献速递神经肿瘤

脑膜瘤5-ALA给药后原卟啉IX实时动力学及与胶质母细胞瘤的比较

Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas.
PubMed 文献 · Acta Neurochir (Wien) · 2020-05-02

结果显示脑膜瘤荧光和PpIX在给药后7–8小时达峰,且给药后5–6小时脑膜瘤荧光强度与PpIX浓度高于胶质母细胞瘤。

要点

  • 脑膜瘤PpIX荧光在5-ALA给药后7–8小时达峰。
  • 给药后5–6小时脑膜瘤荧光和PpIX高于胶质母细胞瘤。
  • 脑膜瘤中PpIX清除似乎快于胶质母细胞瘤。

核心结论

  • 脑膜瘤与胶质母细胞瘤在5-ALA给药后早期PpIX与荧光强度动力学不同。
  • 调整给药时机可能影响术中荧光可见性和荧光引导手术的有用性,需未来研究。

研究设计与样本

  • 将脑膜瘤动力学数据与229例胶质母细胞瘤数据进行比较。

主要发现

  • 43个分析样本均显示荧光(中位数2945.65 a.u.)和PpIX蓄积(中位数18.31 μg/ml)。
  • 术中可见肿瘤荧光样本(N=30)的荧光强度(2961.50 a.u. vs 118.41 a.u.;p < .001)和PpIX浓度(18.72 μg/ml vs .98 μg/ml;p < .001)高于无可见荧光样本(N=2)。
  • ROC分析显示术中可见肿瘤荧光的PpIX截断浓度为3.85 μg/ml(AUC = .992,p = .005),定量荧光截断强度为286.73 a.u.(AUC = .983,p = .006)。
  • 非典型与良性脑膜瘤间荧光强度(p = .356)和PpIX(p = .631)均无差异。
  • 5-ALA给药后7–8小时荧光和PpIX达峰;给药后5–6小时脑膜瘤荧光强度(p = .012)和PpIX浓度(p = .005)高于胶质母细胞瘤。

关键数值与推荐

  • 术中可见肿瘤荧光的PpIX截断浓度为3.85 μg/ml(AUC = .992,p = .005)。
  • 术中可见肿瘤荧光的定量荧光截断强度为286.73 a.u.(AUC = .983,p = .006)。

临床怎么用

  • 脑膜瘤5-ALA荧光引导手术可参考PpIX 3.85 μg/ml和荧光强度286.73 a.u.作为可见荧光的截断值。
  • 脑膜瘤给药后7–8小时荧光达峰,可据此考虑手术时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The usefulness of 5-aminolevulinic acid (5-ALA)-mediated fluorescence-guided surgery (FGS) in meningiomas is intensely discussed. However, data about kinetics of 5-ALA and protoporphyrin (Pp) IX in meningiomas are lacking. METHODS: As the first study so far, we performed longitudinal intraoperative real-time ex situ measurements of fluorescence intensity and PpIX concentrations during FGS of ten benign and two atypical meningiomas. Kinetics were subsequently compared with data from 229 glioblastomas. RESULTS: Spectroscopy revealed fluorescence (median 2945.65 a.u.) and PpIX accumulation (median 18.31 μg/ml) in all 43 analyzed samples. Fluorescence intensity (2961.50 a.u. vs 118.41 a.u.; p < .001) and PpIX concentrations (18.72 μg/ml vs .98 μg/ml; p < .001) were higher in samples with (N = 30) than without (N = 2) visible intraoperative tumor fluorescence. ROC curve analyses revealed a PpIX cut-off concentration of 3.85 μg/ml (AUC = .992, p = .005) and a quantitative fluorescence cut-off intensity of 286.73 a.u. (AUC = .983, p = .006) for intraoperative visible tumor fluorescence. Neither fluorescence intensity (p = .356) nor PpIX (p = .631) differed between atypical and benign meningiomas. Fluorescence and PpIX peaked 7-8 h following administration of 5-ALA. Meningiomas displayed a higher fluorescence intensity (p = .012) and PpIX concentration (p = .005) than glioblastomas 5-6 h after administration of 5-ALA. Although fluorescence was basically maintained, PpIX appeared to be cleared faster in meningiomas than in glioblastomas. CONCLUSIONS: Kinetics of PpIX and fluorescence intensity differ between meningiomas and glioblastomas in the early phase after 5-ALA administration. Modification of the timing of drug administration might impact visibility of intraoperative fluorescence and helpfulness of FGS and should be investigated in future analyses.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Kaneko S, Brokinkel B, Suero Molina E, et al. Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas. Acta Neurochir (Wien). 2020. PMID: 32361907. doi:10.1007/s00701-020-04353-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。